20.04.2020 HumanOptics AG  DE000A1MMCR6

HumanOptics AG: Dr. Pierre Billardon leaves the Management Board on 30 April 2020; Diana Bachmann appointed as his successor


 


DGAP-Media / 20.04.2020 / 17:58

Dr. Pierre Billardon leaves the Management Board on 30 April 2020; Diana Bachmann appointed as his successor

Erlangen, April 20, 2020 - Dr. Pierre Billardon, since January 2017 CEO and since July 2018 sole member of the Management Board of HumanOptics AG ("Company"), will leave the Company at his own request at the end of his contract which runs until 30 April 2020.

"I have informed the Supervisory Board that I do not wish to accept the offered extension. After three successful and exciting years at HumanOptics, it is now time for me to take on new professional challenges. Due to the growth strategy consistently implemented in recent years and in particular the artificial iris, which received FDA approval at the end of May 2018 and health insurance approval at the end of January 2020 in the USA, the course has been set for the next growth phase of HumanOptics." Dr. Pierre Billardon commented on his decision.

Li Lijuan, Chairperson of the Supervisory Board of the Company, regrets this decision and thanks him on behalf of the Supervisory Board and all employees: "Dr. Pierre Billardon has made a significant contribution to the growth of HumanOptics in recent years. We would like to thank him for his extraordinary commitment and the excellent cooperation at all times. Personally and professionally we wish him all the best and continued success for his future career path".

It is intended that Dr. Pierre Billardon will be succeeded by Diana Bachmann, who has been performing the functional tasks of a CFO since May 2018 alongside Dr. Pierre Billardon as Vice-President Finance & Administration. The Supervisory Board of HumanOptics AG intends to appoint Diana Bachmann with effect from 1 May 2020 initially for a term of office until 31 December 2020 as a member of the Management Board of the Company. Diana Bachmann will pursue the growth strategy of the Company together with the Management Team.


Contact:

HumanOptics AG
Investor Relations
Spardorfer Str. 150
91054 Erlangen
Germany
Phone: +49 (0) 9131 50665-0
E-Mail: [email protected]



End of Media Release


Issuer: HumanOptics AG
Key word(s): Enterprise

20.04.2020 Dissemination of a Press Release, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: HumanOptics AG
Spardorfer Str. 150
91054 Erlangen
Germany
Phone: +49 (0)9131 - 50665-60
Fax: +49 (0)9131 - 50665-93
E-mail: [email protected]
Internet: www.humanoptics.de
ISIN: DE000A1MMCR6, DE000A255FK8
WKN: A1MMCR
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Stuttgart
EQS News ID: 1025679

 
End of News DGAP Media

1025679  20.04.2020 

fncls.ssp?fn=show_t_gif&application_id=1025679&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2015 2016 2017 2018 2019 2020 2021e
Umsatzerlöse1 10,51 11,56 11,04 10,68 9,36 10,20 0,00
EBITDA1,2 0,82 0,54 -1,28 -1,27 -1,90 0,80 0,00
EBITDA-Marge3 7,80 4,67 -11,59 -11,89 -20,30 7,84 0,00
EBIT1,4 0,33 0,13 -1,71 -1,76 -2,42 0,34 0,00
EBIT-Marge5 3,14 1,12 -15,49 -16,48 -25,86 3,33 0,00
Jahresüberschuss1 0,16 0,03 -1,78 -1,89 -2,57 -0,25 0,00
Netto-Marge6 1,52 0,26 -16,12 -17,70 -27,46 -2,45 0,00
Cashflow1,7 0,99 0,53 -1,30 -1,84 -1,53 0,30 0,00
Ergebnis je Aktie8 0,05 0,01 -0,58 -0,60 -0,74 -0,07 0,29
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2019 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Ebner Stolz

INVESTOR-INFORMATIONEN
©boersengefluester.de
HumanOptics
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A1MMCR 9,000 Halten 31,39
KGV 2022e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
21,43 34,23 0,63 -57,33
KBV KCV KUV EV/EBITDA
12,06 - 3,35 -18,76
Dividende '19 in € Dividende '20e in € Div.-Rendite '20e
in %
Hauptversammlung
0,00 0,00 0,00 18.12.2020
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
- 03.12.2020
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-0,91% -6,25% 8,43% 7,14%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu HumanOptics AG  ISIN: DE000A1MMCR6 können Sie bei DGAP abrufen

Medtech , A1MMCR , H9O1 , FWB:H9O1